References
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. Jama. 2002;287:2570–81.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.
Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191–201.
Anonymous. Physician’s health study: aspirin and primary prevention of coronary heart disease. N Engl J Med. 1989;321:1825–8.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
Uk P. Intensive blood-glucose control with sulfonureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes. Lancet. 1998;352:837–53.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marx, N. Focussed Section “Effect of Oral Antidiabetic Drugs on Micro- and Macrovascular Complications in Patients with Diabetes Mellitus – Update 2008”. Cardiovasc Drugs Ther 22, 205–206 (2008). https://doi.org/10.1007/s10557-008-6102-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-008-6102-2